DK2569425T3 - Endoribonuklease-sammensætninger og fremgangsmåder til anvendelse deraf - Google Patents

Endoribonuklease-sammensætninger og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2569425T3
DK2569425T3 DK11781086.1T DK11781086T DK2569425T3 DK 2569425 T3 DK2569425 T3 DK 2569425T3 DK 11781086 T DK11781086 T DK 11781086T DK 2569425 T3 DK2569425 T3 DK 2569425T3
Authority
DK
Denmark
Prior art keywords
leu
arg
ser
ala
gly
Prior art date
Application number
DK11781086.1T
Other languages
English (en)
Inventor
Rachel E Haurwitz
Jennifer A Doudna
Blake Wiedenheft
Martin Jinek
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK2569425T3 publication Critical patent/DK2569425T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Claims (23)

1. Csy4-endoribonukleasevariant omfattende en aminosyresekvens, der har mindst ca. 95 % aminosyresekvensidentitet med aminosyresekvensen med SEQ ID NO:101 eller SEQ ID NO: 102 angivet i figur 6, hvor endoribonuklea-sen omfatter en aminosyresubstitution ved His-29, hvor Csy4-endoribonukleasevarianten er enzymatisk inaktiv i fravær af imidazol, og hvor Csy4-endoribonukleasevarianten er aktiverbar i nærvær af imidazol.
2. Csy4-endoribonukleasevariant ifølge krav 1, hvor aminosyresubstitutionen er en His29- til Ala29-substitution.
3. Csy4-endoribonukleasevariant ifølge krav 1, hvor Csy4- endoribonukleasevarianten omfatter en del, der tilvejebringer et detekterbart signal.
4. Csy4-endoribonukleasevariant ifølge krav 3, hvor delen er udvalgt blandt en fluorophor, et kvantepunkt, et enzym, som ikke er endoribonukleasen, eller en nanopartikel.
5. Csy4-endoribonukleasevariant ifølge krav 1, hvor endoribonukleasen er immobiliseret på en uopløselig bærer.
6. Csy4-endoribonukleasevariant ifølge krav 5, hvor den uopløselige bærer er en kugle.
7. Csy4-endoribonukleasevariant ifølge krav 1, hvor Csy4- endoribonukleasevarianten binder et RNA-substrat omfattende nukleotidse-kvensen 5'-GUUCACUGCCGUAUAGGCAGCUAAGAAA-3' (SEQ ID NO:1).
8. Nukleinsyre omfattende en nukleotidsekvens, der koder for Csy4-endoribonukleasevarianten ifølge krav 1.
9. Rekombinant ekspressionsvektor omfattende en nukleotidsekvens, der koder for Csy4-endoribonukleasevarianten ifølge krav 1.
10. Rekombinant ekspressionsvektor ifølge krav 9, hvor nukleotidsekvensen, der koder for Csy4-endoribonukleasevarianten er funktionsmæssigt forbundet med en promoter.
11. Rekombinant ekspressionsvektor ifølge krav 10, hvor promoteren er en inducerbar promoter.
12. In vitro genmodificeret værtscelle omfattende den rekombinante ekspressionsvektor ifølge krav 9.
13. Kit til rensning af et target-RNA, der er til stede i en blandet population af nukleinsyrer, hvilket kit omfatter: Csy4-endoribonucleasevarianten ifølge krav 1.
14. Kit ifølge krav 13, hvor endoribonukleasen er immobiliseret på en uopløselig bærer.
15. Kit ifølge krav 13 eller 14, yderligere omfattende en rekombinant ekspressionsvektor omfattende, i rækkefølge fra 5' til 3' og i funktionsmæssig binding: a) en nukleotidsekvens, der koder for et RNA-substrat, der er specifikt bundet af Csy4-endoribonukleasevarianten ifølge krav 1; b) et multipelt kloningssted, der er egnet til insertion af en nukleinsyre, der koder for target-RNA'et.
16. Kit ifølge krav 15, hvor nukleotidsekvensen, der koder for RNA-substratet, er funktionsmæssigt forbundet med en promoter.
17. Kit ifølge krav 16, hvor promoteren er en inducerbar promoter.
18. Kit ifølge krav 15, hvor RNA-substratet omfatter nukleotidsekvensen 5'-GUUCACUGCCGUAUAGGCAGCUAAGAAA-3' (SEQ ID NO:1).
19. Kit ifølge krav 15, hvor den rekombinante ekspressionsvektor omfatter, insereret i det multiple kloningssted, en nukleotidsekvens, der koder for tar- get-RNA'et.
20. Kit ifølge krav 13, yderligere omfattende en eller flere af (a) imidazol, (b) en eller flere vaskebuffere og (c) en positiv kontrol-ekspressionsvektor.
21. Fremgangsmåde til isolering af et target-RNA, der er til stede i en blandet population af nukleinsyrer, hvilken fremgangsmåde omfatter: a) at bringe en blandet population af nukleinsyrer i kontakt med Csy4-endoribonukleasevarianten ifølge krav 1, hvor Csy4-endoribonukleasevarianten er immobiliseret på en uopløselig bærer, hvor den blandede population af nukleinsyrer omfatter et mærket target-RNA omfattende en genkendelsesnukleotidsekvens, der er specifikt bundet af den immobiliserede Csy4-endoribonukleasevariant, hvorved der dannes et mærket target-RNA-immobiliseret Csy4-endoribonukleasevariant-kompleks, hvor det at bringe i kontakt udføres i en bindingsopløsning uden imidazol; b) at tilsætte imidazol til bindingsopløsningen til en endelig koncentration på fra ca. 100 mM til ca. 500 mM, hvorved der dannes en reaktiveringsopløsning, som enzymatisk reaktiverer den immobiliserede Csy4-endoribonukleasevariant, hvor den reaktiverede immobiliserede Csy4-endoribonukleasevariant spalter target-RNA'et fra markøren; og c) at indsamle det frigjorte target-RNA.
22. Fremgangsmåde ifølge krav 21, yderligere omfattende et vasketrin udført efter trin (a) og før trin (b).
23. Fremgangsmåde til isolering af et polypeptid, der binder et target-RNA, hvilken fremgangsmåde omfatter: a) at bringe et immobiliseret kompleks i kontakt med en flydende opløsning omfattende et polypeptid, der binder target-RNA'et, hvor det immobiliserede kompleks omfatter Csy4-endoribonukleasevarianten ifølge krav 1 og et mærket target-RNA, der omfatter en genkendelsesnukleotidsekvens, der er specifikt bundet af Csy4-endoribonukleasevarianten, hvor det at bringe i kontakt resulterer i binding af polypeptidet til target-RNA'et, hvor det at bringe i kontakt udføres i en bindingsopløsning uden imidazol; og b) at eluere det bundne polypeptid.
DK11781086.1T 2010-05-10 2011-05-09 Endoribonuklease-sammensætninger og fremgangsmåder til anvendelse deraf DK2569425T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33316310P 2010-05-10 2010-05-10
US36562710P 2010-07-19 2010-07-19
US41328710P 2010-11-12 2010-11-12
PCT/US2011/035775 WO2011143124A2 (en) 2010-05-10 2011-05-09 Endoribonuclease compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2569425T3 true DK2569425T3 (da) 2016-10-03

Family

ID=44914921

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11781086.1T DK2569425T3 (da) 2010-05-10 2011-05-09 Endoribonuklease-sammensætninger og fremgangsmåder til anvendelse deraf

Country Status (14)

Country Link
US (3) US9115348B2 (da)
EP (2) EP3078753B1 (da)
JP (1) JP5926242B2 (da)
KR (1) KR101867359B1 (da)
CN (1) CN103038338B (da)
AU (1) AU2011253222B2 (da)
BR (1) BR112012028805A2 (da)
CA (1) CA2798703A1 (da)
DK (1) DK2569425T3 (da)
EA (1) EA024121B9 (da)
ES (1) ES2590343T3 (da)
MX (1) MX2012013037A (da)
SG (1) SG185481A1 (da)
WO (1) WO2011143124A2 (da)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590343T3 (es) 2010-05-10 2016-11-21 The Regents Of The University Of California Composiciones de endorribonucleasas y métodos de uso de las mismas
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
EP4289948A3 (en) 2012-05-25 2024-04-17 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US9102936B2 (en) 2012-06-11 2015-08-11 Agilent Technologies, Inc. Method of adaptor-dimer subtraction using a CRISPR CAS6 protein
US9688971B2 (en) 2012-06-15 2017-06-27 The Regents Of The University Of California Endoribonuclease and methods of use thereof
WO2013192278A1 (en) 2012-06-19 2013-12-27 Regents Of The University Of Minnesota Gene targeting in plants using dna viruses
WO2014018423A2 (en) 2012-07-25 2014-01-30 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing
JP6517143B2 (ja) * 2012-10-23 2019-05-22 ツールゲン インコーポレイテッド 標的ｄｎａに特異的なガイドｒｎａおよびｃａｓタンパク質コード核酸またはｃａｓタンパク質を含む、標的ｄｎａを切断するための組成物、ならびにその使用
US20160017366A1 (en) 2012-12-06 2016-01-21 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
EP2931892B1 (en) 2012-12-12 2018-09-12 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
PL2921557T3 (pl) 2012-12-12 2017-03-31 Broad Inst Inc Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140179770A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
ES2786193T3 (es) 2012-12-12 2020-10-09 Broad Inst Inc Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR20150095861A (ko) 2012-12-17 2015-08-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Rna-가이드된 인간 게놈 조작
EP2971184B1 (en) 2013-03-12 2019-04-17 President and Fellows of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
EP3620534B1 (en) 2013-03-14 2021-10-13 Caribou Biosciences, Inc. Crispr-cas compositions of nucleic acid-targeting nucleic acids
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
KR20230157540A (ko) 2013-03-15 2023-11-16 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US9902973B2 (en) 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
CA3176690A1 (en) 2013-06-04 2014-12-11 President And Fellows Of Harvard College Rna-guided transcriptional regulation
CA2915842C (en) 2013-06-17 2022-11-29 The Broad Institute, Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
KR20160056869A (ko) 2013-06-17 2016-05-20 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
WO2014204727A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
KR20160034901A (ko) 2013-06-17 2016-03-30 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작에 최적화된 ｃｒｉｓｐｒ-ｃａｓ 이중 닉카아제 시스템, 방법 및 조성물
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
US10329587B2 (en) 2013-07-10 2019-06-25 President And Fellows Of Harvard College Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
CA2922089C (en) 2013-08-22 2022-07-05 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
WO2015048707A2 (en) * 2013-09-30 2015-04-02 Regents Of The University Of Minnesota Conferring resistance to geminiviruses in plants using crispr/cas systems
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
EP3080260B1 (en) 2013-12-12 2019-03-06 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
CN106061510B (zh) 2013-12-12 2020-02-14 布罗德研究所有限公司 用于基因组编辑的crispr-cas***和组合物的递送、用途和治疗应用
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3080258A1 (en) 2013-12-12 2016-10-19 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
JP6721508B2 (ja) * 2013-12-26 2020-07-15 ザ ジェネラル ホスピタル コーポレイション 多重ガイドｒｎａ
US11028388B2 (en) 2014-03-05 2021-06-08 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
DK3116997T3 (da) 2014-03-10 2019-08-19 Editas Medicine Inc Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
ES2888976T3 (es) 2014-06-23 2022-01-10 Massachusetts Gen Hospital Identificación no sesgada pangenómica de DSBs evaluada por secuenciación (GUIDE-Seq.)
WO2016007347A1 (en) 2014-07-11 2016-01-14 E. I. Du Pont De Nemours And Company Compositions and methods for producing plants resistant to glyphosate herbicide
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10435685B2 (en) 2014-08-19 2019-10-08 Pacific Biosciences Of California, Inc. Compositions and methods for enrichment of nucleic acids
EP3186376B1 (en) 2014-08-27 2019-03-20 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
EP3191595B1 (en) 2014-09-12 2019-12-25 E. I. du Pont de Nemours and Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
SG10201804715WA (en) 2015-01-28 2018-07-30 Pioneer Hi Bred Int Crispr hybrid dna/rna polynucleotides and methods of use
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
CN113846144B (zh) 2015-03-17 2023-09-26 生物辐射实验室股份有限公司 检测基因组编辑
BR112017017260A2 (pt) 2015-03-27 2018-04-17 Du Pont construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
JP2018522249A (ja) 2015-04-24 2018-08-09 エディタス・メディシン、インコーポレイテッド Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
AU2016280893B2 (en) 2015-06-18 2021-12-02 Massachusetts Institute Of Technology CRISPR enzyme mutations reducing off-target effects
US9580727B1 (en) 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
AU2016316845B2 (en) 2015-08-28 2022-03-10 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
KR20180043369A (ko) 2015-09-11 2018-04-27 더 제너럴 하스피탈 코포레이션 뉴클레아제 dsb의 완전한 호출 및 시퀀싱(find-seq)
CA3000762A1 (en) 2015-09-30 2017-04-06 The General Hospital Corporation Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
WO2017070598A1 (en) 2015-10-23 2017-04-27 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
CA3002827A1 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
JP6882282B2 (ja) 2015-11-03 2021-06-02 プレジデント アンド フェローズ オブ ハーバード カレッジ 三次元核酸含有マトリックスの立体撮像のための方法と装置
EP3371310B1 (en) 2015-12-04 2019-05-01 Caribou Biosciences, Inc. Engineered nucleic-acid targeting nucleic acids
WO2017139309A1 (en) 2016-02-12 2017-08-17 Ceres, Inc. Methods and materials for high throughput testing of mutagenized allele combinations
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
AU2017257624B2 (en) 2016-04-25 2023-05-25 President And Fellows Of Harvard College Hybridization chain reaction methods for in situ molecular detection
KR102458395B1 (ko) 2016-06-02 2022-10-25 시그마-알드리치 컴퍼니., 엘엘씨 프로그램가능한 dna 결합 단백질을 사용한, 표적화된 게놈 변형의 개선
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
AU2017305404B2 (en) 2016-08-02 2023-11-30 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
KR20190067209A (ko) 2016-10-14 2019-06-14 더 제너럴 하스피탈 코포레이션 후성적으로 조절되는 부위-특이적 뉴클레아제
US9816093B1 (en) 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
EP3610009A1 (en) 2017-04-12 2020-02-19 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
BR112019021719A2 (pt) 2017-04-21 2020-06-16 The General Hospital Corporation Variantes de cpf1 (cas12a) com especificidade para pam alterada
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CA3063733A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
ES2913457T3 (es) 2017-06-30 2022-06-02 Inscripta Inc Métodos, módulos, instrumentos y sistemas de procesamiento celular automatizados
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11286468B2 (en) 2017-08-23 2022-03-29 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CA3074927A1 (en) 2017-09-30 2019-04-04 Inscripta, Inc. Flow through electroporation instrumentation
EP3694993A4 (en) 2017-10-11 2021-10-13 The General Hospital Corporation METHOD OF DETECTING A SITE-SPECIFIC AND UNDESIRED GENOMIC DESAMINATION INDUCED BY BASE EDITING TECHNOLOGIES
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11661599B1 (en) 2017-12-14 2023-05-30 National Technology & Engineering Solutions Of Sandia, Llc CRISPR-Cas based system for targeting single-stranded sequences
US20190233816A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
CN108486098B (zh) * 2018-03-06 2021-07-06 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用SLFN13从总RNA中纯化总mRNA的方法
US10443031B1 (en) 2018-03-29 2019-10-15 Inscripta, Inc. Methods for controlling the growth of prokaryotic and eukaryotic cells
US10376889B1 (en) 2018-04-13 2019-08-13 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
AU2019256287A1 (en) 2018-04-17 2020-11-12 The General Hospital Corporation Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10508273B2 (en) 2018-04-24 2019-12-17 Inscripta, Inc. Methods for identifying selective binding pairs
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
CA3108767A1 (en) 2018-06-30 2020-01-02 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
AU2019363487A1 (en) 2018-08-30 2021-04-15 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
AU2019368215B2 (en) 2018-10-22 2023-05-18 Inscripta, Inc. Engineered enzymes
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
US20220073890A1 (en) 2018-12-14 2022-03-10 Pioneer Hi-Bred International, Inc. Novel crispr-cas systems for genome editing
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
GB2601618A (en) 2019-03-19 2022-06-08 Broad Inst Inc Methods and compositions for editing nucleotide sequences
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
EP3947691A4 (en) 2019-03-25 2022-12-14 Inscripta, Inc. SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
RU2707542C1 (ru) 2019-03-28 2019-11-27 Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Способ получения препарата рекомбинантной нуклеазы CAS, по существу, свободного от бактериальных эндотоксинов, полученный данным способом препарат и содержащий его набор для использования в системе CRISPR/Cas
WO2020247587A1 (en) 2019-06-06 2020-12-10 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US11767524B2 (en) * 2019-09-24 2023-09-26 Abclonal Science, Inc. His-MBP tagged DNA endonuclease for facilitated enzyme removal
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
CA3157131A1 (en) 2019-12-10 2021-06-17 Inscripta, Inc. Novel mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
US11008557B1 (en) 2019-12-18 2021-05-18 Inscripta, Inc. Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
EP4096770A1 (en) 2020-01-27 2022-12-07 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
WO2022060749A1 (en) 2020-09-15 2022-03-24 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2023004391A2 (en) 2021-07-21 2023-01-26 Montana State University Nucleic acid detection using type iii crispr complex
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
CN114410635B (zh) * 2022-03-29 2022-06-14 中国科学院天津工业生物技术研究所 威尼斯镰刀菌内源U6启动子及其基于CRISPR/Cas9的基因编辑方法
CN115976080B (zh) * 2022-11-28 2024-04-19 南方医科大学南方医院 一种鉴定与人脑lncRNA互作蛋白的载体及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
CA2623339C (en) 1994-12-09 2012-05-08 David William Holden Virulence genes in the vgc2 cluster of salmonella
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6426513B1 (en) 1998-09-18 2002-07-30 Massachusetts Institute Of Technology Water-soluble thiol-capped nanocrystals
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
US6325144B1 (en) 2000-06-09 2001-12-04 Baker Hughes, Inc. Inflatable packer with feed-thru conduits
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US6576291B2 (en) 2000-12-08 2003-06-10 Massachusetts Institute Of Technology Preparation of nanocrystallites
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
CA2453450A1 (en) 2001-07-20 2003-11-06 Quantum Dot Corporation Luminescent nanoparticles and methods for their preparation
US7268229B2 (en) 2001-11-02 2007-09-11 Promega Corporation Compounds to co-localize luminophores with luminescent proteins
KR101223918B1 (ko) 2003-06-13 2013-01-25 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 Ｒｎａ 인터페라제 및 이의 사용 방법
WO2005074986A2 (en) 2004-02-10 2005-08-18 Genobiotix Aps Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
US7919277B2 (en) 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
JPWO2006123537A1 (ja) * 2005-05-16 2008-12-25 タカラバイオ株式会社 新規なエンドリボヌクレア−ゼ
WO2007013265A1 (ja) 2005-07-26 2007-02-01 Takara Bio Inc. 新規なエンドリボヌクレアーゼ
EP3284833B1 (en) 2005-08-26 2021-12-01 DuPont Nutrition Biosciences ApS Use of crispr associated genes (cas)
US7745190B2 (en) * 2005-09-21 2010-06-29 Takara Bio Inc. Endoribonuclease
EP2426220B1 (en) 2006-05-19 2016-06-22 DuPont Nutrition Biosciences ApS Tagged microorganisms and methods of tagging
WO2009032218A1 (en) 2007-08-29 2009-03-12 Biolume Inc. Bioluminescent endoscopy methods and compounds
WO2010011961A2 (en) * 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
EP2362915B1 (en) 2008-11-07 2016-12-21 DuPont Nutrition Biosciences ApS Bifidobacteria crispr sequences
ES2499032T3 (es) 2008-12-12 2014-09-26 Dupont Nutrition Biosciences Aps Grupo genético de cepas de Streptococcus thermophilus que tiene propiedades reológicas únicas para fermentación láctica
ES2590343T3 (es) 2010-05-10 2016-11-21 The Regents Of The University Of California Composiciones de endorribonucleasas y métodos de uso de las mismas
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
WO2013088446A1 (en) 2011-12-16 2013-06-20 Targetgene Biotechnologies Ltd Compositions and methods for modifying a predetermined target nucleic acid sequence
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing

Also Published As

Publication number Publication date
KR101867359B1 (ko) 2018-07-23
SG185481A1 (en) 2012-12-28
US20150284697A1 (en) 2015-10-08
JP5926242B2 (ja) 2016-05-25
WO2011143124A3 (en) 2012-04-19
US9708646B2 (en) 2017-07-18
AU2011253222A1 (en) 2012-12-06
EP2569425A2 (en) 2013-03-20
JP2013528372A (ja) 2013-07-11
EP3078753A1 (en) 2016-10-12
ES2590343T3 (es) 2016-11-21
AU2011253222B2 (en) 2014-08-21
CA2798703A1 (en) 2011-11-17
EP2569425B1 (en) 2016-07-06
MX2012013037A (es) 2013-07-29
EP3078753B1 (en) 2018-04-18
WO2011143124A2 (en) 2011-11-17
CN103038338A (zh) 2013-04-10
EA024121B9 (ru) 2017-01-30
EA201291024A1 (ru) 2013-11-29
BR112012028805A2 (pt) 2019-09-24
US9605246B2 (en) 2017-03-28
CN103038338B (zh) 2017-03-08
US20170166958A1 (en) 2017-06-15
EP2569425A4 (en) 2014-03-12
KR20130079420A (ko) 2013-07-10
EA024121B1 (ru) 2016-08-31
US9115348B2 (en) 2015-08-25
US20130130248A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
US9708646B2 (en) Endoribonuclease compositions and methods of use thereof
US9688971B2 (en) Endoribonuclease and methods of use thereof
KR102606680B1 (ko) Ｓ. 피오게네스 ｃａｓ９ 돌연변이 유전자 및 이에 의해 암호화되는 폴리펩티드
EP3471749B1 (en) Methods and compositions for detecting a target rna
Froelich et al. A conserved MCM single-stranded DNA binding element is essential for replication initiation
Stamos et al. Structure of a thermostable group II intron reverse transcriptase with template-primer and its functional and evolutionary implications
ES2262524T3 (es) Metodo para la sintesis de fragmentos de dna.
US8841094B2 (en) Homologous recombination method, cloning method, and kit
Montemayor et al. Structural basis of lariat RNA recognition by the intron debranching enzyme Dbr1
Crampton et al. Oligomeric states of bacteriophage T7 gene 4 primase/helicase
US20220372453A1 (en) Non-ltr-retroelement reverse transcriptase and uses thereof
AU2014259510B2 (en) Endoribonuclease compositions and methods of use thereof
Gerber et al. Structural and mechanistic insights into activation of the human RNA ligase RTCB by Archease
Sissler et al. Handling mammalian mitochondrial tRNAs and aminoacyl-tRNA synthetases for functional and structural characterization
Pitolli et al. RNA aptamers developed against tRip: A preliminary approach targeting tRNA entry in Plasmodium
US20230313156A1 (en) Chemical synthesis of large and mirror-image proteins and uses thereof
Suslov The crystal structure of the Varkud satellite ribozyme: Implications for RNA catalysis, biology and evolution
ES2203613T3 (es) Produccion de polipeptidos.
WO2024059719A2 (en) Compositions for preventing repetitive addition of switching oligonucleotides and nonspecific primer extension during cdna synthesis and methods of use thereof
Moore Finding the Molecular Partners of Ccm1p, A Saccaromyces cerevisiae PPR Protein Involved in Mitoribosome Biogenesis
Huang Functional and structural studies of the TY1 retrotransposon in Saccharomyces cerevisiae